COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combin...
Ausführliche Beschreibung
Autor*in: |
N. L. Pogudina [verfasserIn] E. G. Kosolapov [verfasserIn] F. S. Kochenkov [verfasserIn] A. V. Karaulov [verfasserIn] N. L. Bondarenko [verfasserIn] D. V. Blinov [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Russisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Фармакоэкономика - IRBIS LLC, 2019, 10(2017), 2, Seite 12-21 |
---|---|
Übergeordnetes Werk: |
volume:10 ; year:2017 ; number:2 ; pages:12-21 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.17749/2070-4909.2017.10.2.012-021 |
---|
Katalog-ID: |
DOAJ079493866 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ079493866 | ||
003 | DE-627 | ||
005 | 20230410103223.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230307s2017 xx |||||o 00| ||rus c | ||
024 | 7 | |a 10.17749/2070-4909.2017.10.2.012-021 |2 doi | |
035 | |a (DE-627)DOAJ079493866 | ||
035 | |a (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a rus | ||
050 | 0 | |a RM1-950 | |
050 | 0 | |a HB71-74 | |
100 | 0 | |a N. L. Pogudina |e verfasserin |4 aut | |
245 | 1 | 0 | |a COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. | ||
650 | 4 | |a asthma | |
650 | 4 | |a inhaled corticosteroids | |
650 | 4 | |a ics | |
650 | 4 | |a long-acting beta agonists | |
650 | 4 | |a laba | |
650 | 4 | |a vilanterol | |
650 | 4 | |a fluticasone furoate | |
650 | 4 | |a budesonide | |
650 | 4 | |a formoterol | |
650 | 4 | |a fixed-dose combination | |
650 | 4 | |a cost-minimization analysis | |
650 | 4 | |a budget impact analysis | |
653 | 0 | |a Therapeutics. Pharmacology | |
653 | 0 | |a Economics as a science | |
700 | 0 | |a E. G. Kosolapov |e verfasserin |4 aut | |
700 | 0 | |a F. S. Kochenkov |e verfasserin |4 aut | |
700 | 0 | |a A. V. Karaulov |e verfasserin |4 aut | |
700 | 0 | |a N. L. Bondarenko |e verfasserin |4 aut | |
700 | 0 | |a D. V. Blinov |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Фармакоэкономика |d IRBIS LLC, 2019 |g 10(2017), 2, Seite 12-21 |w (DE-627)176061677X |x 20704933 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2017 |g number:2 |g pages:12-21 |
856 | 4 | 0 | |u https://doi.org/10.17749/2070-4909.2017.10.2.012-021 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 |z kostenfrei |
856 | 4 | 0 | |u https://www.pharmacoeconomics.ru/jour/article/view/195 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2070-4909 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2070-4933 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 10 |j 2017 |e 2 |h 12-21 |
author_variant |
n l p nlp e g k egk f s k fsk a v k avk n l b nlb d v b dvb |
---|---|
matchkey_str |
article:20704933:2017----::oprtvcsmnmztoadugtmatnlssfiedsihldotcseodogcigeagns |
hierarchy_sort_str |
2017 |
callnumber-subject-code |
RM |
publishDate |
2017 |
allfields |
10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21 |
spelling |
10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21 |
allfields_unstemmed |
10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21 |
allfieldsGer |
10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21 |
allfieldsSound |
10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21 |
language |
Russian |
source |
In Фармакоэкономика 10(2017), 2, Seite 12-21 volume:10 year:2017 number:2 pages:12-21 |
sourceStr |
In Фармакоэкономика 10(2017), 2, Seite 12-21 volume:10 year:2017 number:2 pages:12-21 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science |
isfreeaccess_bool |
true |
container_title |
Фармакоэкономика |
authorswithroles_txt_mv |
N. L. Pogudina @@aut@@ E. G. Kosolapov @@aut@@ F. S. Kochenkov @@aut@@ A. V. Karaulov @@aut@@ N. L. Bondarenko @@aut@@ D. V. Blinov @@aut@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
176061677X |
id |
DOAJ079493866 |
language_de |
russisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079493866</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2017 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079493866</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. L. Pogudina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled corticosteroids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting beta agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">laba</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vilanterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluticasone furoate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budesonide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">formoterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fixed-dose combination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost-minimization analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budget impact analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. G. Kosolapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">F. S. Kochenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Karaulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. L. Bondarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. V. Blinov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">10(2017), 2, Seite 12-21</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:12-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/195</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">12-21</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
N. L. Pogudina |
spellingShingle |
N. L. Pogudina misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
authorStr |
N. L. Pogudina |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)176061677X |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
20704933 |
topic_title |
RM1-950 HB71-74 COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis |
topic |
misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science |
topic_unstemmed |
misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science |
topic_browse |
misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Фармакоэкономика |
hierarchy_parent_id |
176061677X |
hierarchy_top_title |
Фармакоэкономика |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)176061677X |
title |
COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
ctrlnum |
(DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 |
title_full |
COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
author_sort |
N. L. Pogudina |
journal |
Фармакоэкономика |
journalStr |
Фармакоэкономика |
callnumber-first-code |
R |
lang_code |
rus |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
txt |
container_start_page |
12 |
author_browse |
N. L. Pogudina E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov |
container_volume |
10 |
class |
RM1-950 HB71-74 |
format_se |
Elektronische Aufsätze |
author-letter |
N. L. Pogudina |
doi_str_mv |
10.17749/2070-4909.2017.10.2.012-021 |
author2-role |
verfasserin |
title_sort |
comparative cost-minimization and budget-impact analysis of fixed-dose inhaled corticosteroid / long-acting betaagonist combinations in the treatment of asthma |
callnumber |
RM1-950 |
title_auth |
COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
abstract |
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. |
abstractGer |
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. |
abstract_unstemmed |
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA |
url |
https://doi.org/10.17749/2070-4909.2017.10.2.012-021 https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 https://www.pharmacoeconomics.ru/jour/article/view/195 https://doaj.org/toc/2070-4909 https://doaj.org/toc/2070-4933 |
remote_bool |
true |
author2 |
E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov |
author2Str |
E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov |
ppnlink |
176061677X |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.17749/2070-4909.2017.10.2.012-021 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T23:42:01.001Z |
_version_ |
1803603275679793153 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079493866</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2017 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079493866</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. L. Pogudina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled corticosteroids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting beta agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">laba</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vilanterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluticasone furoate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budesonide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">formoterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fixed-dose combination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost-minimization analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budget impact analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. G. Kosolapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">F. S. Kochenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Karaulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. L. Bondarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. V. Blinov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">10(2017), 2, Seite 12-21</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:12-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/195</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">12-21</subfield></datafield></record></collection>
|
score |
7.4002275 |